Article
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.
Science translational medicine - 4 Feb 2026
Huang Hai-Cheng, Deng Qing, Guo Lei, Gorria Teresa, Pecci Federica, Yang Daniella, Rodig Scott, De Las Casas Luis, Hallin Jill, Christensen James G, Awad Mark M, Xu Lin, Ricciuti Biagio, Akbay Esra A
Abstract excerpt
The development of allele-specific KRAS inhibitors underscores the importance of understanding the distinct tumor biology associated with common KRAS mutations, G12D and G12C, in genetically engineered mouse models (GEMMs) of non-small cell lung cancer (NSCLC) and patient samples. Lung tumors driven by the most common KRAS mutation, G12C, show delayed onset and slower progression compared with those driven by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.